Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy

Glycogen synthesis is normally absent in neurons. However, inclusion bodies resembling abnormal glycogen accumulate in several neurological diseases, particularly in progressive myoclonus epilepsy or Lafora disease. We show here that mouse neurons have the enzymatic machinery for synthesizing glycogen, but that it is suppressed by retention of muscle glycogen synthase (MGS) in the phosphorylated, inactive state. This suppression was further ensured by a complex of laforin and malin, which are the two proteins whose mutations cause Lafora disease. The laforin-malin complex caused proteasome-dependent degradation both of the adaptor protein targeting to glycogen, PTG, which brings protein phosphatase 1 to MGS for activation, and of MGS itself. Enforced expression of PTG led to glycogen deposition in neurons and caused apoptosis. Therefore, the malin-laforin complex ensures a blockade of neuronal glycogen synthesis even under intense glycogenic conditions. Here we explain the formation of polyglucosan inclusions in Lafora disease by demonstrating a crucial role for laforin and malin in glycogen synthesis.

[1]  H. Hohorst.  d-Glucose-6-phosphate and d-Fructose-6-phosphate: Determination with Glucose-6-Phosphate Dehydrogenase and Phosphoglucose Isomerase , 1965 .

[2]  C. Newgard,et al.  Glucose 6-Phosphate Produced by Glucokinase, but Not Hexokinase I, Promotes the Activation of Hepatic Glycogen Synthase* , 1996, The Journal of Biological Chemistry.

[3]  J. Massagué,et al.  Glycogen synthase: A new activity ratio assay expressing a high sensitivity to the phosphorylation state , 1979, FEBS letters.

[4]  Gonzalo R. Lafora,et al.  Beitrag zur Histopathologie der myoklonischen Epilepsie , 1911 .

[5]  S. Ganesh,et al.  Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy , 2006, Journal of Human Genetics.

[6]  R. Michelucci,et al.  A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). , 1999, Human molecular genetics.

[7]  S. Scherer,et al.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy , 1998, Nature Genetics.

[8]  P. Satishchandra,et al.  Familial Progressive Myoclonus Epilepsy: Clinical and Electrophysiologic Observations , 1995, Epilepsia.

[9]  M. Sakai,et al.  Studies in myoclonus epilepsy (Lafora body form) , 1970, Neurology.

[10]  H. Berman,et al.  Overexpression of Protein Targeting to Glycogen (PTG) in Rat Hepatocytes Causes Profound Activation of Glycogen Synthesis Independent of Normal Hormone- and Substrate-mediated Regulatory Mechanisms* , 1998, The Journal of Biological Chemistry.

[11]  Dr. Gonzalo R. Lafora.  Über das Vorkommen amyloider Körperchen im Innern der Ganglienzellen , 1911, Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin.

[12]  M. Coghlan,et al.  Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. , 2003, European journal of biochemistry.

[13]  P. Roach,et al.  Rabbit skeletal muscle glycogen synthase expressed in COS cells. Identification of regulatory phosphorylation sites. , 1994, The Journal of biological chemistry.

[14]  T. Chan,et al.  A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. , 1976, Analytical biochemistry.

[15]  R. K. Simpson.  Nature Neuroscience , 2022 .

[16]  D. Hardie,et al.  Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. , 2003, Diabetes.

[17]  R. R. Cowden,et al.  Myoclonus epilepsy with Lafora bodies. An ultrastruc- tural and cytochemical study. , 1968, Archives of pathology.

[18]  P. Magistretti,et al.  Protein targeting to glycogen mRNA expression is stimulated by noradrenaline in mouse cortical astrocytes , 2000, Glia.

[19]  M. Schlamowitz.  On the nature of rabbit liver glycogen. I. Branching characteristics. , 1951, The Journal of biological chemistry.

[20]  R. Gomis,et al.  Liver Glycogen Synthase but Not the Muscle Isoform Differentiates between Glucose 6-Phosphate Produced by Glucokinase or Hexokinase* , 2002, The Journal of Biological Chemistry.

[21]  Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase , 2005, The FEBS journal.

[22]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.

[23]  Katsuhiro Kobayashi,et al.  Longitudinal Clinicoelectrophysiologic Study of a Case of Lafora Disease Proven by Skin Biopsy , 1990, Epilepsia.

[24]  F. Andermann,et al.  Progressive myoclonus epilepsies: specific causes and diagnosis. , 1986, The New England journal of medicine.

[25]  J. Cavanagh.  Corpora-amylacea and the family of polyglucosan diseases , 1999, Brain Research Reviews.

[26]  O. Baba.  [Production of monoclonal antibody that recognizes glycogen and its application for immunohistochemistry]. , 1993, Kokubyo Gakkai zasshi. The Journal of the Stomatological Society, Japan.

[27]  Carlos Viijlar‐Palasí,et al.  The role of glucose 6‐phosphate in the control of glycogen synthase , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  J. Ferrer,et al.  Muscle glycogen synthase translocates from the cell nucleus to the cytosol in response to glucose , 1997, FEBS letters.

[29]  C. Worby,et al.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Newgard,et al.  Use of recombinant adenovirus for metabolic engineering of mammalian cells. , 1994, Methods in cell biology.

[31]  A. Saltiel,et al.  Identification of Binding Sites on Protein Targeting to Glycogen for Enzymes of Glycogen Metabolism* , 2000, The Journal of Biological Chemistry.

[32]  J. Dixon,et al.  A Unique Carbohydrate Binding Domain Targets the Lafora Disease Phosphatase to Glycogen* , 2002, The Journal of Biological Chemistry.

[33]  J. Serratosa,et al.  Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. , 2003, Human molecular genetics.

[34]  P. Roach,et al.  Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. , 2000, Diabetes.

[35]  S. Scherer,et al.  Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy , 2000, Neurology.

[36]  P. Beighton,et al.  Clinical and Genetic Aspects , 1980 .

[37]  B. Minassian.  Lafora's disease: towards a clinical, pathologic, and molecular synthesis. , 2001, Pediatric neurology.

[38]  F Andermann,et al.  Progressive Myoclonus Epilepsies: Clinical and Genetic Aspects , 1993, Epilepsia.

[39]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[40]  J. A. Thomas,et al.  A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. , 1968, Analytical biochemistry.

[41]  M. Schlamowitz.  On the nature of rabbit liver glycogen. II. Iodine absorption spectrum. , 1951, The Journal of biological chemistry.

[42]  Angus M. Brown.  Brain glycogen re‐awakened , 2004, Journal of neurochemistry.

[43]  F. Graham,et al.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. , 1988, Virology.

[44]  A. Saltiel,et al.  PTG, a Protein Phosphatase 1-Binding Protein with a Role in Glycogen Metabolism , 1997, Science.

[45]  S. Scherer,et al.  Mutations in NHLRC1 cause progressive myoclonus epilepsy , 2003, Nature Genetics.

[46]  N. Delanty,et al.  Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects , 2005, The Lancet Neurology.

[47]  J. D. del Río,et al.  Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation. , 2007, Cerebral cortex.

[48]  R. Gomis,et al.  Control of glycogen deposition , 2003, FEBS letters.